MetaCap

Biomerica Inc. (BMRA)

NASDAQ: BMRAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

1.08-0.01 (-0.92%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BMRA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.64
52-week range
1.01 – 2.94
Day range
1.06 – 1.13
Volume / Avg
5.38K / 72.95K
Beta
—

52-week range

$1.01$2.94

BMRA stock today

Biomerica (BMRA) closed at $1.08 on Nov 20, down 0.92% (-$0.01), versus the S&P 500's 3.70% decline. Trading was light, with 5.38K shares changing hands, about 7% of the average daily volume. At this level, BMRA sits near the bottom of its 52-week range of $1.01 to $2.94: 63.3% below the high, set on Jan 7, 2026 and 6.9% above the low.

BMRA is down 57.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 51.6%. Biomerica has posted a net loss over the last twelve months (EPS of -$1.64), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Biomerica

Company profile

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. Zackary S. Irani
Headquarters
Irvine, CA
Employees
50

Financial highlights

Full financials

In fiscal 2026, Biomerica generated $4.5 million in revenue, down 16.2% from fiscal 2025, its first annual decline since 2025. Biomerica reported a net loss of $3.8 million, compared with a loss of $5.0 million a year earlier. Gross margin was 8.1% (down from 9.4%) and operating margin -119.5%.

Biomerica annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$4.45M$5.31M$5.42M$5.34M$18.87M
Growth-16.16%-1.92%+1.42%-71.71%+162.13%
Net income$-3.77M$-4.97M$-5.98M$-7.14M$-4.53M
EPS (diluted)$-1.30$-2.16$-2.84$-0.50$-0.36

Earnings

Earnings history
Last reported (Aug/2026)
Oct 15, 2026
EPS actual vs est.
$-0.37 vs —

BMRA news

All BMRA news

Biomerica peers

Health Care sector
BMRA peer companies
CompanyPrice% ChgMarket capCompare
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs BMRA
CDIOCardio Diagnostics Holdings Inc.1.60-3.03%$4.74Mvs BMRA
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs BMRA
QCLSQ/C Technologies Inc.0.2784-6.01%$2.40Mvs BMRA
VRAXVirax Biolabs Group Limited0.3319-12.89%$446.40Kvs BMRA
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs BMRA
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs BMRA
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs BMRA

Indexes, lists and sector

Biomerica stock FAQ

What is Biomerica's stock price today?

BMRA last traded at $1.08 as of Nov 20, 4:00 PM EST, down 0.92% on the day. Prices are delayed at least 15 minutes.

Does Biomerica pay a dividend?

No. Biomerica does not currently pay a regular cash dividend.

Who is Biomerica's CEO?

Mr. Zackary S. Irani is the chief executive officer of Biomerica Inc., which has about 50 employees.

Has BMRA ever split its stock?

Yes. The most recent BMRA stock split was a 1-for-8 split on Apr 21, 2025, one of 2 splits on record.

What is the BMRA 52-week high?

The 52-week high for BMRA is $2.94 and the 52-week low is $1.01. The stock is currently 63.3% below its high.

Compare BMRA